20 valent pneumococcal conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Vaxcyte, Inc.

Conditions

Pneumococcal Vaccines

Phase 1

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

CompletedNCT05266456

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2022-02-22End: 2023-01-10Updated: 2024-04-18

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

CompletedNCT06151288

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2023-11-08End: 2024-07-17Updated: 2025-07-28

Related Papers

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.

2023-12-0419 citations